Environmental or self-antigens and homotypic interactions result in BCR and Toll-like receptor (TLR) signaling, amplifying the response of CLL cells to other indicators from your microenvironment and increasing the activation of anti-apoptotic and proliferation pathways.Duvelisib was the second PI3K inhibitor approved because of the FDA, also based